Acrivon Therapeutics, INC Schedule 13G passive stakes

Sands Capital entities and Frank M. Sands jointly report beneficial ownership of 5.3% of Acrivon Therapeutics' common stock as of June 30, 2026.

Citadel Advisors and related entities report a negligible beneficial ownership of 13 shares in Acrivon Therapeutics.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 5.5% in Acrivon Therapeutics, Inc. common stock.

Citadel and its affiliates, including Kenneth Griffin, report a 4.9% passive beneficial ownership in Acrivon Therapeutics, Inc. as of September 30, 2025.

Sands Capital Life Sciences Pulse Fund II, L.P. and affiliates reported a 6.8% beneficial ownership stake in Acrivon Therapeutics, Inc.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a complete divestment of their beneficial ownership in Acrivon Therapeutics, Inc., holding 0.0% of common stock as of June 2, 2025.

Citadel Advisors LLC and affiliated entities, including Kenneth Griffin, have disclosed a 6.0% beneficial ownership stake in Acrivon Therapeutics, Inc. as of March 31, 2025.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively report a 9.9% beneficial ownership stake in Acrivon Therapeutics, Inc., holding 3,104,139 shares of common stock.